Organogenesis readies new expansion plans

With the first phase of its expansion plan complete, Canton, MA-based Organogenesis is now blueprinting a new R&D center and manufacturing plant. The biotech says that it will have invested $63 million in the expansion by the time it is all completed in 2013. The developer also says that Saudi officials have approved its treatment for chronic wounds and foot ulcers. Story

Suggested Articles

Frontage is Growing to Meet All Your Needs! Click Here to Learn About the Next Generation of Frontage.

Cara Care, a digital health startup focused on digestive diseases, raised $7 million to bring its mobile app to more patients in the U.S.

Investors looked past the headline success of Sci-B-Vac, zeroed in on the failure to achieve a secondary objective and sent VBI’s stock down 66%.